{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:04:03Z","timestamp":1777503843549,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Immunology, asthma & Allergy Research Institute, Tehran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000850","name":"National Heart and Lung Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.pupt.2020.101886","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T05:41:40Z","timestamp":1578375700000},"page":"101886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Asthma phenotypes and T-bet protein expression in cells treated with Fluticasone Furoate\/Vilanterol"],"prefix":"10.1016","volume":"60","author":[{"given":"Zahra","family":"Alizadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esmaeil","family":"Mortaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzieh","family":"Mazinani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Reza","family":"Fazlollahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Heidarnezhad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Adcock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Moin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pupt.2020.101886_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/MCP.0000000000000434","article-title":"Precision medicine in asthma: linking phenotypes to targeted treatments","volume":"24","author":"Chung","year":"2018","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"1","key":"10.1016\/j.pupt.2020.101886_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1939-4551-7-12","article-title":"Allergic diseases and asthma: a global public health concern and a call to action","volume":"7","author":"Pawankar","year":"2014","journal-title":"World Allergy Organ J."},{"key":"10.1016\/j.pupt.2020.101886_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0065-2776(01)77019-8","article-title":"Mouse models of allergic airway disease","volume":"77","author":"Lloyd","year":"2001","journal-title":"Adv. Immunol."},{"issue":"3","key":"10.1016\/j.pupt.2020.101886_bib4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1067\/mai.2003.169","article-title":"The role of T lymphocytes in the pathogenesis of asthma","volume":"111","author":"Larche","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10","key":"10.1016\/j.pupt.2020.101886_bib5","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200801-086OC","article-title":"IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice","volume":"178","author":"Wakashin","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5553","key":"10.1016\/j.pupt.2020.101886_bib6","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1126\/science.1065544","article-title":"Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet","volume":"295","author":"Finotto","year":"2002","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.pupt.2020.101886_bib7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/ni.2059","article-title":"T-bet in disease","volume":"12","author":"Lazarevic","year":"2011","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.pupt.2020.101886_bib8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0092-8674(00)80702-3","article-title":"A novel transcription factor, T-bet, directs Th1 lineage commitment","volume":"100","author":"Szabo","year":"2000","journal-title":"Cell"},{"issue":"5553","key":"10.1016\/j.pupt.2020.101886_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1126\/science.1065543","article-title":"Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells","volume":"295","author":"Szabo","year":"2002","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.pupt.2020.101886_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019889","article-title":"Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORgammat cells in allergic inflammation, local lung distribution and chemokine gene expression","volume":"6","author":"Lu","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.pupt.2020.101886_bib11","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2006-04-015016","article-title":"T-bet is a critical determinant in the instability of the IL-17-secreting T-helper phenotype","volume":"108","author":"Mathur","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pupt.2020.101886_bib12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1139\/bcb-2017-0126","article-title":"Role of the TSLP-DC-OX40L pathway in asthma pathogenesis and airway inflammation in mice","volume":"96","author":"Feng","year":"2018","journal-title":"Biochem. Cell Biol."},{"issue":"5","key":"10.1016\/j.pupt.2020.101886_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00151829-200403050-00002","article-title":"Combination therapy of long-acting beta2-adrenoceptor agonists and corticosteroids for asthma","volume":"3","author":"Chung","year":"2004","journal-title":"Treat. Respir. Med."},{"issue":"4","key":"10.1016\/j.pupt.2020.101886_bib14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/thoraxjnl-2013-203600","article-title":"Once-daily fluticasone furoate (FF)\/vilanterol reduces risk of severe exacerbations in asthma versus FF alone","volume":"69","author":"Bateman","year":"2014","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.pupt.2020.101886_bib15","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.clinthera.2014.03.014","article-title":"Tolerability of fluticasone furoate\/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma","volume":"36","author":"Oliver","year":"2014","journal-title":"Clin. Ther."},{"issue":"8","key":"10.1016\/j.pupt.2020.101886_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/dtb.2014.8.0273","article-title":"Relvar ellipta for asthma","volume":"52","year":"2014","journal-title":"Drug Ther. Bull."},{"key":"10.1016\/j.pupt.2020.101886_bib17","series-title":"A Language and Environment for Statistical Computing","author":"R Core Team R","year":"2014"},{"issue":"3","key":"10.1016\/j.pupt.2020.101886_bib18","first-page":"3809","article-title":"Upregulation of Tim-3 on CD4(+) T cells is associated with Th1\/Th2 imbalance in patients with allergic asthma","volume":"8","author":"Tang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"3","key":"10.1016\/j.pupt.2020.101886_bib19","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jaci.2006.12.643","article-title":"T-bet inhibits both TH2 cell-mediated eosinophil recruitment and TH17 cell-mediated neutrophil recruitment into the airways","volume":"119","author":"Fujiwara","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.pupt.2020.101886_bib20","first-page":"1","article-title":"Glucocorticoid receptor nuclear translocation in CD4 T cells from severe and moderate asthmatic patients treated with fluticasone\/vilanterol","volume":"17","author":"Alizadeh","year":"2018","journal-title":"Iran. J. Allergy, Asthma Immunol."},{"issue":"11","key":"10.1016\/j.pupt.2020.101886_bib21","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/all.12480","article-title":"Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial","volume":"69","author":"Busse","year":"2014","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.pupt.2020.101886_bib22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jaip.2014.02.010","article-title":"Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial","volume":"2","author":"Bleecker","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"4","key":"10.1016\/j.pupt.2020.101886_bib23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2500\/aap.2016.37.3968","article-title":"Efficacy and safety evaluation of once-daily fluticasone furoate\/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid\/long-acting beta2-agonist","volume":"37","author":"Lin","year":"2016","journal-title":"Allergy Asthma Proc."},{"key":"10.1016\/j.pupt.2020.101886_bib24","article-title":"Vilanterol and fluticasone furoate for asthma","volume":"9","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.pupt.2020.101886_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.anai.2016.03.035","article-title":"Once-daily fluticasone furoate and vilanterol for adolescents and adults with symptomatic asthma: a systematic review with meta-analysis","volume":"116","author":"Rodrigo","year":"2016","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"5","key":"10.1016\/j.pupt.2020.101886_bib26","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jaip.2018.12.021","article-title":"Assessment of adherence and asthma medication ratio for a once-daily and twice-daily inhaled corticosteroid\/long-acting beta-agonist for asthma","volume":"7","author":"Stanford","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"5","key":"10.1016\/j.pupt.2020.101886_bib27","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jaip.2019.03.022","article-title":"New targeted therapies for uncontrolled asthma","volume":"7","author":"Corren","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"2","key":"10.1016\/j.pupt.2020.101886_bib28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2500\/aap.2016.37.3928","article-title":"Th1\/Th2\/Th17 cells imbalance in patients with asthma with and without psychological symptoms","volume":"37","author":"Zhu","year":"2016","journal-title":"Allergy Asthma Proc."},{"issue":"2","key":"10.1016\/j.pupt.2020.101886_bib29","first-page":"82","article-title":"Role of epigenetics in the pathogenesis of asthma","volume":"16","author":"Alizadeh","year":"2017","journal-title":"Iran. J. Allergy, Asthma Immunol."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553919301476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553919301476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:29:37Z","timestamp":1761082177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553919301476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":29,"alternative-id":["S1094553919301476"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2020.101886","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asthma phenotypes and T-bet protein expression in cells treated with Fluticasone Furoate\/Vilanterol","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2020.101886","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101886"}}